Table 3.

Steady state pharmacokinetics of stavudine (30/40 mg bi-daily)

	Cmax (μg/ml)	Cmin (μg/ml)	Tmax (h)	AUC(0-t) (μg/ml-h)	t½ (h)
Overall	0.37	0.015	1.0	1.38	3.32
n = 14	(0.20–0.76)	(0.001–0.11)	(0.5–2.0)	(0.59–2.20)	(0.50–6.58)
CD4 counts (cell/μl)
< 200	0.33	0.020	1.0	1.37	2.71
n = 8	(0.20–0.57)	(0.001–0.11)	(1.0–2.0)	(0.59–2.20)	(0.50–6.58)
≥ 200	0.53*	0.025	1.0	1.47	3.32
n = 6	(0.31–0.76)	(0.01–0.03)	(1.0)	(1.29–2.17)	(2.35–5.71)
Sex
Males	0.37	0.015	1.0	1.36	2.82
n = 12	(0.20–0.76)	(0.001–0.11)	(0.5–2.0)	(0.59–2.20)	(0.50–6.58)
Females	0.39	0.03	0.75	1.62	3.58
n = 2	(0.21–0.56)	(0.01–0.05)	(0.5–1.0)	(1.58–1.67)	(3.53–3.63)
BMI (kg/m2)
< 18.5	0.38	0.030	0.75	1.51	3.36
n = 8	(0.21–0.76)	(0.004–0.11)	(0.5–1.0)	(0.92–2.20)	(1.79–6.58)
≥ 18.5	0.37	0.01	1.0	1.37	2.32
n = 6	(0.20–0.57)	(0.001–0.03)	(0.5–2.0)	(0.59–1.58)	(0.50–5.64)
Dose
30 mg	0.35	0.01	1.0	1.38	2.94
n = 10	(0.20–0.57)	(0.001–0.11)	(0.5–2.0)	(0.59–2.20)	(0.50–6.58)
40 mg	0.38	0.03	0.75	1.35	3.02
n = 4	(0.31–0.76)	(0.02–0.03)	(0.5–1.0)	(1.29–2.17)	(2.53–5.71)

C_max, peak concentration; C_min, minimum concentration; T_max, time to attain C-_max; AUC, area under the plasma concentration vs. time curve; t_½, half life;

^*P < 0.05 compared to the group with CD4 counts < 200 cells/μl. Values are shown as median and range given in parentheses